Palbociclib (PD-0332991) HCl

Licensed by Pfizer 製品コードS1116

Palbociclib (PD-0332991) HCl化学構造

分子量(MW):483.99

Palbociclib (PD-0332991) HCl is a highly selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM in cell-free assays, respectively. It shows no activity against CDK1/2/5, EGFR, FGFR, PDGFR, InsR, etc. Phase 3.

サイズ 価格(税別)  
JPY 18260.00
JPY 28220.00
JPY 94620.00

カスタマーフィードバック(9)

  • PD-0332991 causes inhibition of proliferation of EAC cells in a dose-dependent manner. Western blots showing the phosphorylation status of pRB at Ser780 and Ser795 after incubation with 125 nmol/L PD-0332991 for 24 and 72 hours. Reduction in cyclin A expression and the expression of RB2 (p130) tumor suppressor 72 hours after PD-0332991 treatment are shown (bottom). Total pRB (RB1) and actin are loading controls and T293 cell lysate (293) is a positive control for total pRB and phospho-pRB (Ph-RB). E, anchorage-independent growth of the 3 cell lines in the presence or absence (Cnt) of 125 nmol/L PD-0332991 for 3 weeks.

    Clin Cancer Res 2011 17(13), 4513-22. Palbociclib (PD-0332991) HCl purchased from Selleck.

    b, c MelJuso cells were treated for 12–48 h with 1 µM Selumetinib or 5 µM Palbociclib and the cells were fixed, stained with propidium iodide and cell cycle distribution was determined by flow cytometry (b) and whole cell extracts were fractionated by SDS-PAGE, transferred onto PVDF membrane and immuno-blotted with the indicated antibodies (c). Data is from a single experiment representative of three separate experiments with similar results. The data in (b) are mean ± S.D. from a single experiment with three replicate dishes of cell per data point; similar results were obtained in two additional experiments

    Cell Mol Life Sci, 2016, 73(4):883-900. Palbociclib (PD-0332991) HCl purchased from Selleck.

  • (A) Percentage of DN3a cells in S-phase (as gated on DAPI profile) from control (Zfp36l1/2fl/fl) and Zfp36l1/2fl/fl; CD2Cre (DCKO) mice, after 1 d of treatment with vector or palbociclib (drug).

    J Immunol, 2016, 197(7):2673-85. Palbociclib (PD-0332991) HCl purchased from Selleck.

     

    Patient tumor cell sensitivity to combinatorial treatment with histone deacetylase (HDAC)/cyclin-dependent kinase (CDK) inhibitors in 3-D culture. The effect of each drug or drug combination was assessed by fluorescent dye to identify live (green) and dead cells (red). Cells from breast reduction patients were used as non-cancer control in the assay.

    Pharmacogenomics J 2013 13(1), 94-104. Palbociclib (PD-0332991) HCl purchased from Selleck.

  • The expression of respective proteins in CDK4/6-Rb-apoptosis pathway in cells was examined by Western blot after 3 days of palbociclib treatment.

    Biochim Biophys Acta, 2018, 1864(5 Pt A):1573-1582. Palbociclib (PD-0332991) HCl purchased from Selleck.

     

    Cdk4 is upregulated in ARMS and mMSCs transfected with PAX7-FKHR fusion gene (MP7F), and can be specifi cally inhibited. D: IF results showing overexpression of cdk4 in MP7F cells compared to parental mMSCs and reduced expression of cdk4 after treatment of MP7F cells with the cdk4 inhibitor, PD-0332991. E: IF results showing MyoD1 expression in parental mMSCs cells, and MP7F cells untreated and after treatment with the cdk4 inhibitor, PD-0332991.

    Clin Transl Oncol 2012 14(3), 197-206 . Palbociclib (PD-0332991) HCl purchased from Selleck.

  • WM3734 melanoma cells were treated by PD-0332991 for 36 hours; melanoma cells treated by Doxorubicin (DXR)  at 0.5 μM is included as a control.

     

     

    Dr. Gao Zhang of University of Pennsylvania. Palbociclib (PD-0332991) HCl purchased from Selleck.

    Serum-deprived T98G glioma cells are restimulated with serum(FBS) with or without 1 μΜ PD-0332991.

     

     

    Dr. Sabine Paternot and Dr Pierre Roger of IRIBHM, ULB, Brussels. Palbociclib (PD-0332991) HCl purchased from Selleck.

  • P16INK4A knockdown in INK4A/ARF-wt human glioma cell LN319 potentiates PDGF-Apromoted anchorage-dependent growth in vitro. Soft agar growth of Ink4a/Arf-deficient mAst and LN444 cells treated with PD0332991. (A) IB analysis. (B) Quantification of soft agar assays. β-actin was used as a loading control in all IB experiments. Data are presented as mean ± s.d. and representative of two independent experiments. **, P < 0.01; ***, P < 0.001

    Dr. Kun-Wei Liu from University of Pittsburgh. Palbociclib (PD-0332991) HCl purchased from Selleck.

製品安全説明書

CDK阻害剤の選択性比較

生物活性

製品説明 Palbociclib (PD-0332991) HCl is a highly selective inhibitor of CDK4/6 with IC50 of 11 nM/16 nM in cell-free assays, respectively. It shows no activity against CDK1/2/5, EGFR, FGFR, PDGFR, InsR, etc. Phase 3.
特性 Non-cytotoxic, and halts cancer cell growth & could be used in glioblastoma that has relapsed after temozolomide treatment (a chemotherapeutic used to treat many cancers).
ターゲット
CDK4/CyclinD3 [1]
(Cell-free assay)
CDK4/CyclinD1 [1]
(Cell-free assay)
CDK6/CyclinD2 [1]
(Cell-free assay)
9 nM 11 nM 15 nM
体外試験

PD 0332991 has little effect on other protein kinases including EGFR, FGFR, PGFR, IR. PD 0332991 is a non-ATP competitive inhibitor of Cdk4. PD 0332991 inhibits MDA-MB-435 breast carcinoma cells with IC50 of 66 nM, which is due to reduced Rb phosphorylation at Ser780. PD 0332991 inhibits thymidine incorporation into the DNA of Rb-positive human breast, colon, and lung carcinomas as well as human leukemias, with IC50 values ranging from 0.04-0.17 μM. PD 0332991 shows no activity in Rb-negative cells. PD 0332991 causes an accumulation of cells in G1 in MDA-MB-453 breast and Colo-205 carcinoma cells. [1] PD 0332991 also shows activity in 5T33MM myeloma cells (immunocompetent model) and sensitizes the cells to killing by bortezomib. [2] PD 0332991 inhibits luminal ER-positive as well as HER2-amplified breast cancer cell lines including MDA-MB-175, ZR-75-30, CAMA-1, MDA-MB-134, HCC-202 and UACC-893. PD 0332991 enhances the activity of tamoxifen and trastuzumab in these cell lines. PD 0332991 enhances the sensitivity of tamoxifen in the MCF7 tamoxifen-resistant cells. [3] A recent study shows that PD 0332991 could suppress malignant rhabdoid tumor (MRT) cell lines including MP-MRT-AN, KP-MRT-RY, G401, KP-MRT-NS and the sensitivity of the MRT cell lines to PD 0332991 is inversely correlated with expression of p16. [4]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MOLM13 MoPVT4lv[XOnIFHzd4F6 MXSyOEBp NH;VTHlKdmirYnn0bY9vKG:oIFPET|Qh[XO|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBT[iCyaH;zdIhwenmuYYTpc44hf2m2aDDJR|UxKG:oIECuNFAzKM7:TR?= MYSyOFY1OTFyMx?=
COLO205 NUHGd2FGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFj0XFg4OiCq NYCyRWI5SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[XO|ZYPz[YQh[XNiaX7jc5Jxd3KjdHnvckBw\iCdM1jdeIh6dWmmaX7lJIlvfG9iRF7BJJdqfGhiSVO1NEBw\iByLkCzOkDPxE1? MUmyOFY1OTFyMx?=
U937 M1nPTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI\DfmM4OiCq NFLMcGNCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBie3Onc4Pl[EBieyCrbnPvdpBwemG2aX;uJI9nKFt|SG30bJlucWSrbnWgbY51dyCGTlGge4l1cCCLQ{WwJI9nKDBwMUSg{txO Ml;iNlQ3PDFzMEO=
MOLM13 Mmq3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH6xc3Q4OiCq Ml3WRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDoeY1idiCPT1zNNVMh[2WubIOgbIFz[m:{aX7nJGZNXDNiSWTEJI12fGGwdDDhd5Nme3OnZDDhd{BqdmOxcoDvdoF1cW:wIH;mJHs{UF22aIntbYRqdmViaX70c{BFVkFid3n0bEBKSzVyIH;mJFAvODl4IN88US=> NInWTW8zPDZ2MUGwNy=>
MOLM13 NI\XRVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnzzO|IhcA>? MWjBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IIPvdoFn\W6rYj3y[ZNqe3SjboSgbJVu[W5iTV;MUVE{KGOnbHzzJIF{e2W|c3XkJIF{KGmwY3;ydI9z[XSrb36gc4YhYzOKXYTofY1q\GmwZTDpcpRwKESQQTD3bZRpKEmFNUCgc4YhOC5yOU[g{txO NX7qeohPOjR4NEGxNFM>
MDA-MB-435 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NInPdmEzPCCq NV\ZSVRJUUN3ME2wMlE3KM7:TR?= M4T5UVE2QDBzOEOx
K562 NITjZXhEgXSxdH;4bYMhSXO|YYm= Mor5PVYhcA>? NWO2dnRnTE2VTx?= MUDJR|UxRTJizszN NUfZUlhSOjR2MUe1OlY>
DU145 MYHDfZRwfG:6aXOgRZN{[Xl? NGP2NFk6PiCq MkDwSG1UVw>? MXLJR|UxRTdwNTFOwG0> NUHEcXVuOjR2MUe1OlY>
MDA-MB-231 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWWxJO69VQ>? MYqyOEBp MVLEUXNQ M1XRVGNmdGxiY4njcIUh[XK{ZYP0JIF{e2W|c3XkJIF{KGGlY4XteYxifGmxbjDheEBIOSCyaHHz[S=> NFrENGkzPDRzN{W2Oi=>
MCF7 MnXkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVT2fXJ2OSEQvF2= MV:yOEBp NFrXcINFVVOR NFSwRo5E\WyuIHP5Z4xmKGG{cnXzeEBie3Onc4Pl[EBieyCjY3P1cZVt[XSrb36gZZQhTzFicHjhd4U> MojHNlQ1OTd3Nk[=
MCF7 NH3rO|hMcW6jc3WgRZN{[Xl? NY\mWHVJPSEQvF2= NES1[IQzPCCq NFH5enZFVVOR MojNTY5pcWKrdHnvckBw\iC{ZXPvcYJqdmGwdDDDSGs1N2O7Y3zpcmQyKGG|c3Xzd4VlKGG|IHnubIljcXSrb36gc4YhemW2aX7vZoxie3SxbXGgdIhwe3Cqb4L5cIF1cW:wIHH0JHNmejd6MB?= M37wZlI1PDF5NU[2
MDA-MB-231 Mo[1T4lv[XOnIFHzd4F6 NY\YdHFHPSEQvF2= NVixUGZ[OjRiaB?= MXvEUXNQ MknaTY5pcWKrdHnvckBw\iC{ZXPvcYJqdmGwdDDDSGs1N2O7Y3zpcmQyKGG|c3Xzd4VlKGG|IHnubIljcXSrb36gc4YhemW2aX7vZoxie3SxbXGgdIhwe3Cqb4L5cIF1cW:wIHH0JHNmejd6MB?= M3HONVI1PDF5NU[2
MDA-MB-231 MnvSSpVv[3Srb36gRZN{[Xl? Mn\TNU0yOCEQvF2= MWGyOEBp NEjXd2xFVVOR NHLP[VNld2W|IH7veEBqdmS3Y3WgZZBweHSxc3nzJIF{e2W|c3XkJIF{KFCDUmCgZ4xm[X[jZ3W= MlPxNlQ1OTd3Nk[=
MCF7 MoPmSpVv[3Srb36gRZN{[Xl? MVuxMVExKM7:TR?= NF\IXGozPCCq M4HGRmROW09? MUjkc4V{KG6xdDDpcoR2[2ViYYDvdJRwe2m|IHHzd4V{e2WmIHHzJHBCWlBiY3zlZZZi\2V? M4D4NVI1PDF5NU[2
MDA-MB-231 NYOzSG1RTnWwY4Tpc44hSXO|YYm= NGKzOooxNjVvMTFOwG0> NXHCTIVEPDhiaB?= NUnUSYFjTE2VTx?= MkHEbIF{KG6xIFPlcIwh[3mlbHWgZZJz\XO2IHHzd4V{e2WmIHHzJIFk[3WvdXzheIlwdiCjdDDzeYIuTzFicHjhd4U> M{Gy[FI1PDF5NU[2
MCF7 NHGwW2VHfW6ldHnvckBCe3OjeR?= MnTCNE42NTFizszN MkHhOFghcA>? NWq5XJVZTE2VTx?= NWLrWmhmcGG|IH7vJGNmdGxiY4njcIUh[XK{ZYP0JIF{e2W|c3XkJIF{KGGlY4XteYxifGmxbjDheEB{fWJvR{GgdIhie2V? M2fkcVI1PDF5NU[2
697 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEO0dHpKSzVyPUG0PE4{QCCwTR?= M{TCdHNCVkeHUh?=
P12-ICHIKAWA NH;DW4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVHnWIc3UUN3ME25Ok4xPCCwTR?= NXSyOlZCW0GQR1XS
NB69 NHz4PIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1zhfGlEPTB;MU[xMlghdk1? MonMV2FPT0WU
EoL-1 Mn7lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXjJR|UxRTF6Nz6yOkBvVQ>? NXvRbnhJW0GQR1XS
BHT-101 NGnMPVFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYPzN4E5UUN3ME2xPVgvOjVibl2= M{TUPXNCVkeHUh?=
SK-NEP-1 M3;qcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXHoWVV2UUN3ME2yNlAvODJibl2= NX20eJppW0GQR1XS
MHH-NB-11 M4XwO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYn2TmZuUUN3ME2yNlAvOTlibl2= NXTGW3FsW0GQR1XS
AsPC-1 NEDFVnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWjJR|UxRTJ3Mj61N{BvVQ>? MV;TRW5ITVJ?
ES1 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGLFXmxKSzVyPUK1Ok4zPSCwTR?= NHX6Z|NUSU6JRWK=
LAMA-84 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH[5PY1KSzVyPUK1PE4yQSCwTR?= MlvoV2FPT0WU
MOLT-16 MmC3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWHxeHl1UUN3ME2yOVgvPDlibl2= MVHTRW5ITVJ?
ES7 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX3BN3lxUUN3ME2yO|MvODlibl2= MV\TRW5ITVJ?
KY821 MlfCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NU\CWoJuUUN3ME2zNVQvOSCwTR?= Ml;HV2FPT0WU
RT-112 NFO5UFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV7rfGU{UUN3ME2zNlEvODVibl2= M3jGZXNCVkeHUh?=
HL-60 M4C0eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF\nNm5KSzVyPUO0NE43PiCwTR?= NE\GWlZUSU6JRWK=
MOLT-4 M1PIcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{S4UGlEPTB;M{S1MlE{KG6P MkHuV2FPT0WU
KARPAS-45 NVqwRmF[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{DXb2lEPTB;M{e2MlE3KG6P NGLHZ29USU6JRWK=
SK-N-AS NVPO[3J[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{TxVWlEPTB;M{i3Mlg{KG6P MnL2V2FPT0WU
CTB-1 NXXGO3ZpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{jkemlEPTB;NEC1MlAzKG6P NYDnUpRCW0GQR1XS
NKM-1 MnLLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEC5do9KSzVyPUSxNU45QSCwTR?= MXPTRW5ITVJ?
HTC-C3 NH\PVG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVu4e|k1UUN3ME20N|IvQTVibl2= M3TwSXNCVkeHUh?=
BE-13 MkO5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlTpTWM2OD12NESuNlchdk1? MYDTRW5ITVJ?
KOSC-2 Ml;aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1HtXWlEPTB;NE[2Mlkhdk1? MnzpV2FPT0WU
NB14 NWHINJZoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV3JR|UxRTR6Mz61PEBvVQ>? NYnHU5hbW0GQR1XS
CAL-27 NFn6VnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVXaNph[UUN3ME20PVQvPTlibl2= MmjzV2FPT0WU
H9 NV2xUmdyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml6zTWM2OD12OUWuOFMhdk1? M3nMRXNCVkeHUh?=
RS4-11 M1WxXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH3uPWpKSzVyPUWwOE44OyCwTR?= MWLTRW5ITVJ?
PA-1 NFrXV4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1H6ZmlEPTB;NUC5Mlg3KG6P M{C1cnNCVkeHUh?=
MV-4-11 NUnUcHFjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVXJR|UxRTVzMz64OUBvVQ>? MYXTRW5ITVJ?
OS-RC-2 NVLXenFST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoLITWM2OD13MkGuOlIhdk1? MUnTRW5ITVJ?
RPMI-8226 MknxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFm4cHJKSzVyPUWyOk45PiCwTR?= NHrRNVFUSU6JRWK=
HGC-27 MlTzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUjRVGU3UUN3ME21OlQvQTlibl2= M1O2SXNCVkeHUh?=
CHP-212 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFjHbXZKSzVyPUW5N{42QSCwTR?= MlvCV2FPT0WU
NB10 M3r2RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1PFZmlEPTB;NUm5MlE5KG6P MVrTRW5ITVJ?
HH M13PTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUO2SoQ3UUN3ME21PVkvPDNibl2= M2L5c3NCVkeHUh?=
EW-16 M3;WR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn23TWM2OD14MEOuOVIhdk1? NFfzN|hUSU6JRWK=
ES8 NU\xSm1VT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MonqTWM2OD14MEWuNlEhdk1? MYLTRW5ITVJ?
HAL-01 NULmZpl4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYjJR|UxRTZyNT62O{BvVQ>? NYO1Umg6W0GQR1XS
A204 NH\mNpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFvSc4tKSzVyPU[zN{46OSCwTR?= NIH0V4ZUSU6JRWK=
MHH-PREB-1 MoLKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnuwTWM2OD14M{[uPVkhdk1? NVrX[VlQW0GQR1XS
EM-2 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUf6VINJUUN3ME22OVAvPjRibl2= NHexPYZUSU6JRWK=
BV-173 MlvJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVfJR|UxRTZ3Mj60PEBvVQ>? NV\XUnV2W0GQR1XS
ONS-76 NX7IUZVlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2e1Z2lEPTB;Nke3MlgzKG6P MV;TRW5ITVJ?
KM-H2 M37ROmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXqyTVI3UUN3ME22PVUvPTRibl2= MnOzV2FPT0WU
D-263MG MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYrJR|UxRTdzNz6xNkBvVQ>? NXX2Sm1UW0GQR1XS
ES3 MkfiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVXmUmNiUUN3ME23NlgvQTNibl2= NGq1V2VUSU6JRWK=
VA-ES-BJ NXW5c4tmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkHhTWM2OD15M{KuNlchdk1? M1nDOXNCVkeHUh?=
NBsusSR MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M16zbGlEPTB;N{SyMlk6KG6P NF;hW4hUSU6JRWK=
NCI-H520 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYGxVVdUUUN3ME23OFYvPTJibl2= NG[3bVJUSU6JRWK=
ES5 M1nRfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWHpbZJPUUN3ME23OVIvQCCwTR?= MlrJV2FPT0WU
T-24 M121dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHOwR5lKSzVyPUe3PE44OSCwTR?= NX;jNHloW0GQR1XS
SW962 M3q3d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVfHcIdiUUN3ME24NFgvPjNibl2= MULTRW5ITVJ?
EW-3 M37kcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3O4ZWlEPTB;OEC4Mlc3KG6P M{L5T3NCVkeHUh?=
RXF393 NFnmVFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUi0dpZzUUN3ME24NVIvPzlibl2= NV\OWlBIW0GQR1XS
U251 NVX3cItXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYPIRVJTUUN3ME24NVMvQDhibl2= M3z0VXNCVkeHUh?=
CAMA-1 MkXMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW\zVZpSUUN3ME24N|MvQTRibl2= NHnVT4tUSU6JRWK=
JVM-3 NVvQ[nFDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3TlTGlEPTB;OEWxMlc5KG6P MUnTRW5ITVJ?
COLO-800 NF74fJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWHnSFE3UUN3ME24PVcvPzhibl2= MV;TRW5ITVJ?
OVCAR-5 Mo[zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFnJVYhKSzVyPUmwNE4yKG6P NW\sSZFFW0GQR1XS
LB1047-RCC MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml;GTWM2OD17MkeuOVYhdk1? MV\TRW5ITVJ?
SW954 M2PvbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXXJR|UxRTl{OT60NUBvVQ>? NIrUO25USU6JRWK=
J-RT3-T3-5 M3;VZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoXpTWM2OD17M{[uNFYhdk1? MXPTRW5ITVJ?
Mewo MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWjmfY5pUUN3ME25N|YvPiCwTR?= M3XMUXNCVkeHUh?=
NCI-H1770 NYfHe21yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV[4U2c4UUN3ME25OFAvPTVibl2= MWTTRW5ITVJ?
HO-1-N-1 M1XSbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVWxXZZvUUN3ME25OlIvQDFibl2= M4rKcnNCVkeHUh?=
HSC-3 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXXpT|dDUUN3ME25OlYvPDhibl2= Mle3V2FPT0WU
TYK-nu MoTNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWTrNohqUUN3ME25PVgvOjVibl2= MX\TRW5ITVJ?
KYSE-150 NVX3cVFmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M37NZWlEPTB;MT6wNFA4PiEQvF2= M1XsWXNCVkeHUh?=
SN12C MoDKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MY\JR|UxRTFwMEC4O|Uh|ryP NVXhZZplW0GQR1XS
MOLT-13 MmmxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmC3TWM2OD1zLkCxOFIyKM7:TR?= MnPlV2FPT0WU
TE-11 MmnrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHu1NmdKSzVyPUGuNFQ5OTJizszN NIL0[YpUSU6JRWK=
DB NH\PeINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGTQVXVKSzVyPUGuNFczPzNizszN MXvTRW5ITVJ?
CAL-39 NUGwZWRkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M17lcmlEPTB;MT6wO|UzOiEQvF2= M1\LS3NCVkeHUh?=
A3-KAW MmHsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHXGUldKSzVyPUGuNFg1ODhizszN NXi2e3ZrW0GQR1XS
CHP-134 NVrJVJVYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGTRVJdKSzVyPUGuNVE5ODdizszN NYPrbWk1W0GQR1XS
TGW M37MR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NInNNGFKSzVyPUGuNVI{QTVizszN M4\BdHNCVkeHUh?=
QIMR-WIL MlfOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmLWTWM2OD1zLkGzNVM1KM7:TR?= MlXDV2FPT0WU
NCI-SNU-1 NILLSZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH;IeIRKSzVyPUGuNVY{PTRizszN NYO3c3RUW0GQR1XS
CGTH-W-1 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXjjeWFsUUN3ME2xMlE4OTh4IN88US=> M4D1OXNCVkeHUh?=
MHH-ES-1 MnrhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXexV4xpUUN3ME2xMlE4QTh4IN88US=> MlnHV2FPT0WU
LB2241-RCC MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHrhXHhKSzVyPUGuNVg3OiEQvF2= Mm\2V2FPT0WU
ML-2 NYXucHVWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3fMZWlEPTB;MT6yNFc{PCEQvF2= NGTKXJdUSU6JRWK=
COR-L23 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NU\xS2d3UUN3ME2xMlIzQTN|IN88US=> Mo[yV2FPT0WU
BFTC-905 NULrR4JJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NITPTIpKSzVyPUGuNlQzPjdizszN NIru[WtUSU6JRWK=
Hs-578-T NUnnXYhNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVvJR|UxRTFwMkW4NVch|ryP NIDxZ3ZUSU6JRWK=
KG-1 M2LnXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3vNfmlEPTB;MT6yOlY5PiEQvF2= NX:3[nJNW0GQR1XS
HEL NGC5cG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGW3Xm9KSzVyPUGuNlk{OzhizszN Mnj5V2FPT0WU
A549 MkW0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MknYTWM2OD1zLkK5N|k6KM7:TR?= M2juSXNCVkeHUh?=
COLO-741 NEKzOJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn[3TWM2OD1zLkOyNFg6KM7:TR?= NX76TmdkW0GQR1XS
PC-3 M4LZSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MknBTWM2OD1zLkO1NlIyKM7:TR?= M4\oSnNCVkeHUh?=
HOS MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXnNVmJwUUN3ME2xMlM2Ojl4IN88US=> MV;TRW5ITVJ?
HT-1080 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3vIbmlEPTB;MT6zO|UyQSEQvF2= NY\LWZFrW0GQR1XS
TE-8 MnfLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYLJR|UxRTFwNEG3O|Qh|ryP NInMeWtUSU6JRWK=
BHY M13ReWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGDJ[5ZKSzVyPUGuOFY6OjNizszN NIP5dmNUSU6JRWK=
BB65-RCC MoLqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXHJR|UxRTFwNUC1Nlgh|ryP MX\TRW5ITVJ?
HN MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUDKd3J{UUN3ME2xMlU1ODdzIN88US=> MUnTRW5ITVJ?
NCI-H441 M2i1dmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M17r[GlEPTB;MT61OFkxPyEQvF2= MX3TRW5ITVJ?
RPMI-8866 NWXFcJZzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3SzfmlEPTB;MT61PFUxPyEQvF2= NWXNWmF6W0GQR1XS
CAL-62 M13Bfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWHFTms{UUN3ME2xMlYxQDZ{IN88US=> NHjzOHFUSU6JRWK=
MG-63 M3TBVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{SydGlEPTB;MT62NVgyOyEQvF2= NWqyOVRHW0GQR1XS
SK-LU-1 MnXuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml\ITWM2OD1zLk[yNVUzKM7:TR?= MnLOV2FPT0WU
BCPAP M1nacGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFTBZVVKSzVyPUGuOlY1PTdizszN MnuwV2FPT0WU
22RV1 M1XVNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3W1PGlEPTB;MT62O|g1OyEQvF2= NX7xRWNMW0GQR1XS
T47D MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmfnTWM2OD1zLk[4NFYyKM7:TR?= NXrVc4hbW0GQR1XS
MSTO-211H M4TRNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUHJR|UxRTFwNkm2NFMh|ryP NEjLV3pUSU6JRWK=
DEL MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{LLdGlEPTB;MT63NFI4OyEQvF2= MnXnV2FPT0WU
H4 NWiwc2J6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3zP[2lEPTB;MT63N|IyOiEQvF2= NYjLepBlW0GQR1XS
CAL-51 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NE[2ZXBKSzVyPUGuO|Q5PTVizszN MYXTRW5ITVJ?
ABC-1 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUHQVmx3UUN3ME2xMlc5PTh{IN88US=> NHnFW5lUSU6JRWK=
MZ2-MEL NWjMUmpZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV3JR|UxRTFwN{m1OFIh|ryP MnzZV2FPT0WU
YKG-1 NGfI[WpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUfJR|UxRTFwOEGwOlEh|ryP NIrRbFhUSU6JRWK=
KM12 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVfJR|UxRTFwOEG2NFIh|ryP NITJbpBUSU6JRWK=
L-363 MlH2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NETQUY5KSzVyPUGuPFc1OTJizszN MnnsV2FPT0WU
KU812 M1vXVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVfIfYlRUUN3ME2xMlg6Ojh{IN88US=> MYnTRW5ITVJ?
LOXIMVI M3fzTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHPGXGhKSzVyPUGuPVEzOjhizszN M2TNeXNCVkeHUh?=
G-401 NIX6SXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWPq[Hg{UUN3ME2xMlkzPDJ6IN88US=> MUjTRW5ITVJ?
SW780 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXjJR|UxRTFwOU[yOFYh|ryP MVPTRW5ITVJ?
SW872 M1TlS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF7kUZlKSzVyPUGuPVg{OyEQvF2= NYn1VmdvW0GQR1XS
NB7 MoXlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MojqTWM2OD1zLkm5N|I{KM7:TR?= Mn\sV2FPT0WU
T98G NXTYUnk4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXrJR|UxRTJwMEC2OlYh|ryP NETlO|VUSU6JRWK=
SW1710 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NW[zWJZmUUN3ME2yMlA3QTR3IN88US=> M3S0O3NCVkeHUh?=
NCI-H1573 NEfHO29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFnGO5lKSzVyPUKuNFczQThizszN NVXBSJZxW0GQR1XS
KE-37 M3;Q[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NELmUYxKSzVyPUKuNFg6PTFizszN M2PFc3NCVkeHUh?=
786-0 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnThTWM2OD1{LkG1OFM6KM7:TR?= MXLTRW5ITVJ?
SAS M2XJOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWHJR|UxRTJwMkCzO|Qh|ryP M4HPd3NCVkeHUh?=
CAL-54 M1PlO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4LSU2lEPTB;Mj6yNFQyOyEQvF2= MXzTRW5ITVJ?
SF268 Mo\zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnPyTWM2OD1{LkKzNVIzKM7:TR?= M1vsPHNCVkeHUh?=
SW620 NHvwUXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2fab2lEPTB;Mj6yOlE3QSEQvF2= MX3TRW5ITVJ?
MN-60 M4Xy[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkDzTWM2OD1{LkOxNFYh|ryP MXLTRW5ITVJ?
EFO-27 NF20UG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3S0ZWlEPTB;Mj6zNlA2QCEQvF2= NG\ZUZlUSU6JRWK=
NCI-H747 M{TjU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmLqTWM2OD1{LkOyNVk6KM7:TR?= NWDs[FdXW0GQR1XS
HCC2218 MkDiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M37KW2lEPTB;Mj6zOVM4PCEQvF2= NEXOW4dUSU6JRWK=
MIA-PaCa-2 NGPLbJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEL5dnpKSzVyPUKuN|Y1OzdizszN NXLXR284W0GQR1XS
SJSA-1 NFPvUG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXPJR|UxRTJwM{e3PVYh|ryP NF3PVW1USU6JRWK=
RKO MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn3aTWM2OD1{LkO4OFk3KM7:TR?= NV7kZ4hkW0GQR1XS
NB6 MmDOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXPqZ|dIUUN3ME2yMlQxOzd2IN88US=> MlHCV2FPT0WU
ES4 NHvydY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX3rRWIzUUN3ME2yMlQ2PDJ{IN88US=> MmW3V2FPT0WU
EGI-1 NEC1UXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVXRXZh6UUN3ME2yMlQ3QDh|IN88US=> M2LzTnNCVkeHUh?=
CTV-1 M3flNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYnJR|UxRTJwNUK3O|Mh|ryP MnvoV2FPT0WU
NCI-H1355 M4XRNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlXNTWM2OD1{LkW1PVUyKM7:TR?= MX;TRW5ITVJ?
GT3TKB MoTNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUD3UY9kUUN3ME2yMlU6OTl7IN88US=> MljiV2FPT0WU
SK-HEP-1 NHroWmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHzTelBKSzVyPUKuOVkzPjZizszN NFfGSlRUSU6JRWK=
GAMG M3zEfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWP3bldnUUN3ME2yMlU6Ozl2IN88US=> MXzTRW5ITVJ?
SK-MES-1 MlrvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYHJR|UxRTJwNkG4NFMh|ryP NE\ZbndUSU6JRWK=
RO82-W-1 NXrF[m9[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnnxTWM2OD1{Lk[yNFU4KM7:TR?= NGX5PYZUSU6JRWK=
ECC10 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWi1RYlsUUN3ME2yMlcxOjB4IN88US=> NImyNGtUSU6JRWK=
MCF7 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M33SdGlEPTB;Mj63NVQ3PCEQvF2= NWXwb3hsW0GQR1XS
D-283MED Mm\4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEHNfmVKSzVyPUKuO|I1OyEQvF2= Mm\DV2FPT0WU
RPMI-7951 MnS4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmXyTWM2OD1{Lke1Olk1KM7:TR?= MUfTRW5ITVJ?
Ramos-2G6-4C10 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlviTWM2OD1{Lke3NFk6KM7:TR?= NXfaWJM4W0GQR1XS
KGN NIf1eXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4HLV2lEPTB;Mj64NVg5PCEQvF2= MXPTRW5ITVJ?
NUGC-3 NYLafYRpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWXJR|UxRTJwOEK1NFUh|ryP MUHTRW5ITVJ?
NCI-H292 NHzVfI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoDLTWM2OD1{Lki1NFU{KM7:TR?= M3TYe3NCVkeHUh?=
Becker NELSV3JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYmwcJNHUUN3ME2yMlk2QDN{IN88US=> MUfTRW5ITVJ?
NCI-H1299 M{j4UGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2C2Z2lEPTB;Mz6wOVI3OyEQvF2= M{T5enNCVkeHUh?=
ETK-1 MlfJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXXJR|UxRTNwMEW0N{DPxE1? M3v1RXNCVkeHUh?=
TK10 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoD5TWM2OD1|LkKwNVY2KM7:TR?= NF3ZRWVUSU6JRWK=
VMRC-RCZ MmXoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoKwTWM2OD1|LkO2OFg5KM7:TR?= MVvTRW5ITVJ?
YH-13 NIL3b5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnnvTWM2OD1|LkS0NFc6KM7:TR?= MYnTRW5ITVJ?
DU-145 Mn\iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1zGTGlEPTB;Mz60OlI3QSEQvF2= MUDTRW5ITVJ?
SW1088 NX7sUVdkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmfoTWM2OD1|LkS3OFch|ryP MWDTRW5ITVJ?
HOP-92 NUX1d4RpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYHJR|UxRTNwNUCzOFIh|ryP M2PEXnNCVkeHUh?=
KP-N-YS NHvFOZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1fMWmlEPTB;Mz62NlE{QSEQvF2= MVPTRW5ITVJ?
NCI-H460 M2LZUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWrJR|UxRTNwNk[3N{DPxE1? M{S4eXNCVkeHUh?=
U-2-OS NUG1c4NIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWLJR|UxRTNwN{K1N|Uh|ryP NWnwVlFlW0GQR1XS
A101D M33wcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHvHXYFKSzVyPUOuO|Y6OzZizszN NH;0Zm1USU6JRWK=
MDA-MB-231 NEHNOWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFnRNWtKSzVyPUOuPFE6PTFizszN M3K3NnNCVkeHUh?=
IST-MES1 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGDTc3RKSzVyPUOuPFMzKM7:TR?= M3PCenNCVkeHUh?=
COR-L105 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXzJR|UxRTRwMEG4JO69VQ>? M2XDU3NCVkeHUh?=
NCI-H1437 M3;ZWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3XlO2lEPTB;ND6wNlMxOiEQvF2= MoTxV2FPT0WU
CAL-85-1 NFrJVmxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWLaeJp5UUN3ME20MlAzPDZzIN88US=> MWPTRW5ITVJ?
MZ1-PC NX\ieFdoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWjJR|UxRTRwMUi1OVYh|ryP MU\TRW5ITVJ?
VM-CUB-1 M{i1S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUjJR|UxRTRwM{GyPFQh|ryP M{TR[HNCVkeHUh?=
CHL-1 NHrrdZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUnJR|UxRTRwM{KxOlkh|ryP MkDLV2FPT0WU
MDA-MB-361 NGr6V5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEnoc4dKSzVyPUSuN|MyPTNizszN NWj2foFxW0GQR1XS
NCI-H661 NWLzcWFXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MknmTWM2OD12LkWwNFkzKM7:TR?= MlnsV2FPT0WU
EW-11 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFryc5lKSzVyPUSuOVIzOzFizszN MmLQV2FPT0WU
BEN M4\wTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV7EXJJlUUN3ME20MlUzQDF3IN88US=> MWLTRW5ITVJ?
BFTC-909 MlrQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn3ETWM2OD12LkW2Nlc2KM7:TR?= M1W0SHNCVkeHUh?=
NCI-H2087 MmHsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXXJR|UxRTRwNUixOlQh|ryP MVLTRW5ITVJ?
RVH-421 MnvtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYfJR|UxRTRwNk[2PUDPxE1? MVfTRW5ITVJ?
P30-OHK NYPieZZDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4iy[2lEPTB;ND62PFAxQCEQvF2= MnvnV2FPT0WU
NCI-H28 M{Xq[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHzCVXNKSzVyPUSuPFE3PjFizszN MlHwV2FPT0WU
ES6 MnrSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX6wfJhbUUN3ME20Mlg{ODF4IN88US=> MWfTRW5ITVJ?
769-P MoLmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYS0NYY2UUN3ME20Mlg2QTJ4IN88US=> NGHHPHdUSU6JRWK=
OE33 NVzBVm5bT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn\2TWM2OD12Lki4NVYyKM7:TR?= NXHjbZlRW0GQR1XS
SW982 NUTyNopjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWnJR|UxRTRwOUWwOlEh|ryP MUjTRW5ITVJ?
A388 NEOyOVdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYryUJhsUUN3ME21MlAzQTh|IN88US=> NInicZBUSU6JRWK=
TI-73 Mkn5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1fvU2lEPTB;NT6wOlE6PCEQvF2= M33oeXNCVkeHUh?=
HCT-116 MkDZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmrZTWM2OD13LkC5PFg6KM7:TR?= MlfxV2FPT0WU
HuP-T3 MknSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2jsWWlEPTB;NT6xPFcxQSEQvF2= MVXTRW5ITVJ?
G-402 M1jYVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWnJR|UxRTVwMUm0NVYh|ryP MYXTRW5ITVJ?
NCI-H1792 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MknETWM2OD13LkK0OlIzKM7:TR?= M1K0XnNCVkeHUh?=
NCI-H209 NXfPd5p{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXjucWpQUUN3ME21MlI2QTR{IN88US=> NXfrRnJOW0GQR1XS
NCI-H1650 Ml[5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWXPbG5jUUN3ME21MlMxPjN2IN88US=> NUDDWHZ4W0GQR1XS
LCLC-97TM1 NEm4bI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIDRPWVKSzVyPUWuN|E5ODhizszN M{H5T3NCVkeHUh?=
S-117 NVjtOo42T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4HIOWlEPTB;NT6zOlk4PiEQvF2= MY\TRW5ITVJ?
GI-ME-N M2nnZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4jiZWlEPTB;NT6zPVY5OSEQvF2= MkfhV2FPT0WU
NCI-H2122 NInYS|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkDwTWM2OD13LkS5N|k4KM7:TR?= MknQV2FPT0WU
NCI-H1793 NELZe29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1\GcmlEPTB;NT62O|U6OyEQvF2= MnPnV2FPT0WU
C2BBe1 M2\GXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHXm[|NKSzVyPUWuO|AxQDhizszN Mne0V2FPT0WU
TE-12 NWD1e5NIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmnqTWM2OD13LkiwOVU3KM7:TR?= M4DkRXNCVkeHUh?=
LCLC-103H Mn20S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV24[WQ2UUN3ME21MlkyPyEQvF2= M4fpPHNCVkeHUh?=
A673 NVfrOm5ET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYjJR|UxRTVwOUG5N|Ih|ryP NHjjUlBUSU6JRWK=
BB30-HNC M4Xv[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4DveGlEPTB;NT65PFM3KM7:TR?= MXHTRW5ITVJ?
SF295 MlW0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mk\STWM2OD14LkCwOFIzKM7:TR?= Ml34V2FPT0WU
KU-19-19 M13nNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU\JR|UxRTZwMEG3N|Eh|ryP MnrUV2FPT0WU
CFPAC-1 M{DNcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWjJR|UxRTZwMES0OFMh|ryP NYHKO2pbW0GQR1XS
LoVo M2rsNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmC2TWM2OD14LkC1NFY{KM7:TR?= NXLHOmh4W0GQR1XS
8505C MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1rQVmlEPTB;Nj6wO|U4OyEQvF2= M2PyR3NCVkeHUh?=
GMS-10 M4X6fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmjVTWM2OD14LkG1NFAzKM7:TR?= MoKzV2FPT0WU
Ca9-22 M3roVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MomwTWM2OD14LkG2O|Eh|ryP MmnXV2FPT0WU
DOK MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4jiNmlEPTB;Nj6yNlA4OiEQvF2= MWPTRW5ITVJ?
FADU M1jPR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm[zTWM2OD14LkK2NFM6KM7:TR?= M2H1NnNCVkeHUh?=
BxPC-3 NEPpcHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3y5T2lEPTB;Nj6yO|MzKM7:TR?= MX3TRW5ITVJ?
CAL-33 Mk[0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVLJR|UxRTZwMkmyNFEh|ryP NW\FTlJHW0GQR1XS
SHP-77 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHrvZ49KSzVyPU[uN|E2OTJizszN Ml7jV2FPT0WU
LXF-289 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoH4TWM2OD14LkOzOFU2KM7:TR?= MYTTRW5ITVJ?
GB-1 NG\vdWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2e0XmlEPTB;Nj6zPFIh|ryP MkjRV2FPT0WU
KS-1 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4DxdGlEPTB;Nj6zPFQ1PyEQvF2= Mn3jV2FPT0WU
D-502MG M{jGXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIeydWFKSzVyPU[uOFI{PzZizszN MWfTRW5ITVJ?
LAN-6 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2rL[GlEPTB;Nj61NVAzOyEQvF2= M2\FRXNCVkeHUh?=
H-EMC-SS NXz3dXpGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW\JR|UxRTZwNU[xOFch|ryP MYXTRW5ITVJ?
LC-2-ad NFnGRVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXXJR|UxRTZwNkCwO|Yh|ryP NV\zOoI5W0GQR1XS
NCI-H1693 NIL6W|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGLaXndKSzVyPU[uOlIzOTVizszN MnH0V2FPT0WU
SK-N-FI NH3VU4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlHDTWM2OD14Lke1NFQ1KM7:TR?= NGfjeIhUSU6JRWK=
D-423MG M3fOU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{PDOmlEPTB;Nj63OlEyPyEQvF2= NV:xT3RpW0GQR1XS
KNS-42 NU\4TWNjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M37vTmlEPTB;Nj63PFE6PyEQvF2= NV30fGttW0GQR1XS
GCT MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3jITmlEPTB;Nj65N|gh|ryP MlP5V2FPT0WU
DSH1 M2P6Zmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGPMXoRKSzVyPUeuNFY{OyEQvF2= M4\O[XNCVkeHUh?=
D-247MG MkLrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MW\JR|UxRTdwMEe4PFEh|ryP NUSxeWlUW0GQR1XS
NCI-SNU-5 NGrjc3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXXKWnFIUUN3ME23MlE5OzdzIN88US=> MkDDV2FPT0WU
TE-6 M1PUemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH3CcYlKSzVyPUeuNlA3ODFizszN MVfTRW5ITVJ?
NOMO-1 NEe2UJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1vhSmlEPTB;Nz6yNlEzPyEQvF2= Mk\NV2FPT0WU
NB17 NXezc5ZUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MojpTWM2OD15LkOwN|A6KM7:TR?= MofwV2FPT0WU
EW-22 NVrudGFlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo\XTWM2OD15LkO0N|Q5KM7:TR?= M1\LSnNCVkeHUh?=
EW-13 M1\xWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIrzbVNKSzVyPUeuN|UyPjJizszN M2fwRnNCVkeHUh?=
DOHH-2 NVLDcldXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnnkTWM2OD15LkS0NFIh|ryP MXjTRW5ITVJ?
TGBC1TKB NWq5U5FPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoDiTWM2OD15LkS5PFk6KM7:TR?= MlfOV2FPT0WU
GR-ST MlXJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFnhUYZKSzVyPUeuOVI2QTRizszN MX3TRW5ITVJ?
KYSE-520 M3TmSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1TEU2lEPTB;Nz61OVUyPSEQvF2= Ml3nV2FPT0WU
CAPAN-1 NFXtcopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFrke|ZKSzVyPUeuOVk2OSEQvF2= NYfxUXBwW0GQR1XS
HCE-4 NEX1OoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M333bmlEPTB;Nz62NlI4QSEQvF2= NEH5SWJUSU6JRWK=
MLMA NYPCXXU4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHTuVFlKSzVyPUeuOlI6PTdizszN M2fXbnNCVkeHUh?=
HT-144 NYPjW2c3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH\qR3hKSzVyPUeuOlU{PjhizszN NXLQb4t{W0GQR1XS
KYSE-180 NHTmU5JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmjnTWM2OD15LkexNVY6KM7:TR?= MVnTRW5ITVJ?
TE-5 NUTVfGhtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVXJR|UxRTdwOUW5O|Eh|ryP NXLqXG9LW0GQR1XS
IGROV-1 NVnNVFlLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGniO3hKSzVyPUeuPVg2PTFizszN NHfmNItUSU6JRWK=
NCI-H1581 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWXJR|UxRThwMEGyJO69VQ>? NVvHZmxvW0GQR1XS
SW1990 MkXPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlrXTWM2OD16LkC0OlU6KM7:TR?= Mn\XV2FPT0WU
EFM-19 M2POc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkOxTWM2OD16LkC4OVQ2KM7:TR?= MXfTRW5ITVJ?
OGR-1 NWL2bG03T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MknBTWM2OD16LkSzNFI{KM7:TR?= MUPTRW5ITVJ?
U-118-MG MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVPJR|UxRThwNEO0OlMh|ryP NIjIbm1USU6JRWK=
SK-OV-3 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXrxd2tDUUN3ME24MlQ3PzZ3IN88US=> NXjldYtRW0GQR1XS
KNS-62 Mo\sS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2TsXGlEPTB;OD61NVc3OSEQvF2= NY[5V5RpW0GQR1XS
GOTO NYLPXG1WT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWfONXI{UUN3ME24MlU4PjN3IN88US=> NIXmW3dUSU6JRWK=
8305C NYDpZVRYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXfhSoVxUUN3ME24MlcxPDh2IN88US=> NU\kZ|BLW0GQR1XS
RPMI-2650 NYDXNJJpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGXPfm9KSzVyPUiuO|E6PTVizszN M3vnUnNCVkeHUh?=
NEC8 MkK0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml;0TWM2OD16Lke0N|A4KM7:TR?= M1;kfnNCVkeHUh?=
KYSE-450 Moi3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkL0TWM2OD16Lki2OVQ5KM7:TR?= MYnTRW5ITVJ?
RMG-I MoDtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2rRN2lEPTB;OT6xOFA2QCEQvF2= NGLpcIFUSU6JRWK=
CAKI-1 NVPjV2FoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmTXTWM2OD17LkOxPVc6KM7:TR?= NVnNR4FEW0GQR1XS
KYSE-510 MnnCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGDFZ3NKSzVyPUmuN|U4PzhizszN Mn\rV2FPT0WU
A4-Fuk M3nJ[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXzWRlgzUUN3ME25MlM3PzBzIN88US=> M4H0THNCVkeHUh?=
AN3-CA NX;yOJE{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVn5cY4xUUN3ME25MlQ2PDR2IN88US=> M{XmdHNCVkeHUh?=
SK-N-DZ M1zxemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1rucmlEPTB;OT63Nlg1QSEQvF2= NX7yV5dRW0GQR1XS
HSC-2 MkTGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFn2cVRKSzVyPUmuO|Y3OjlizszN M2HZV3NCVkeHUh?=
EW-1 M2HDSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NULBdY1sUUN3ME25Mlc6OzZ7IN88US=> MUDTRW5ITVJ?
D-566MG M4jEe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG\lU2NKSzVyPUmuPFM3PjRizszN NG\0OlNUSU6JRWK=
COLO-792 NUG3OYNTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUTJR|UxRTlwOUi3OFYh|ryP MnrMV2FPT0WU
TE-10 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWrJR|UxRTFyLkCzPVYh|ryP NE[5fG5USU6JRWK=
NCI-H650 NUjjPJEyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFH6TI1KSzVyPUGwMlQzQDZizszN Ml3QV2FPT0WU
U-266 MlfXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXLJR|UxRTFyLkS1OUDPxE1? NEfyOJdUSU6JRWK=
Detroit562 NInV[FFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFXKemZKSzVyPUGxMlA2OTVizszN NEK1[YJUSU6JRWK=
NH-12 MmXBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVH6O4Q4UUN3ME2xNU4yPDR4IN88US=> M3jXdHNCVkeHUh?=
CO-314 NXG4dYt4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH3NZpJKSzVyPUGxMlI5PDJizszN MnrLV2FPT0WU
IST-MEL1 NWrQcGQ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmPwTWM2OD1zMT61N|I{KM7:TR?= Mlr5V2FPT0WU
KNS-81-FD MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{jPZ2lEPTB;MUGuOVUzPyEQvF2= M{flVXNCVkeHUh?=
SW1463 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml6xTWM2OD1zMT61PVg6KM7:TR?= MWTTRW5ITVJ?
NCI-H23 Mn7ES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIjsOIRKSzVyPUGxMlY2PTJizszN M2\2OXNCVkeHUh?=
SK-MEL-2 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFTQfpZKSzVyPUGxMlcyQTdizszN MUfTRW5ITVJ?
NB13 NUH1TVlYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml21TWM2OD1zMj6xOFk2KM7:TR?= NWXyXVFGW0GQR1XS
Daoy MoTCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkXvTWM2OD1zMj6yPFU3KM7:TR?= NFewcmVUSU6JRWK=
NCI-H1623 NF7YT49Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUfJR|UxRTF{LkO4NFEh|ryP MnjNV2FPT0WU
NMC-G1 NGXvRYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFLrXlVKSzVyPUGyMlcyPyEQvF2= MoHGV2FPT0WU
DK-MG NXL0enAyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFOwfHhKSzVyPUGyMlk1QDJizszN Mlv6V2FPT0WU
TCCSUP MlWyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1TNRWlEPTB;MUOuNVI5PCEQvF2= MYnTRW5ITVJ?
SCC-15 MoD1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVvJR|UxRTF|LkK2OVEh|ryP MUHTRW5ITVJ?
NOS-1 NG\n[4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWjJR|UxRTF|LkK4PVMh|ryP MX3TRW5ITVJ?
RH-1 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHrVeItKSzVyPUGzMlMxOzdizszN MXXTRW5ITVJ?
SK-MEL-3 NV\3ZlhuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWLJR|UxRTF|LkO3Nlgh|ryP MoPOV2FPT0WU
NB5 NV7yVlhQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGTLdGZKSzVyPUGzMlQxPjdizszN MVfTRW5ITVJ?
SNU-387 M3LIZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF3td4JKSzVyPUGzMlUxPzJizszN NHrVbnJUSU6JRWK=
CAL-120 M1j0ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2WzRmlEPTB;MUOuOlcyQCEQvF2= NGnuTJhUSU6JRWK=
Mo-T NVTLUZhwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYrJR|UxRTF|LkewO{DPxE1? MnTmV2FPT0WU
LNCaP-Clone-FGC M3TEU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUnZVJp5UUN3ME2xN{44QTl{IN88US=> MYTTRW5ITVJ?
CAN M4jHc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlXETWM2OD1zND6wNlg5KM7:TR?= MnfRV2FPT0WU
SK-MEL-30 NYHMbWlWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlG4TWM2OD1zND6wOlMh|ryP MlnUV2FPT0WU
COLO-678 NXnNe3NFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVXJR|UxRTF2LkC4NlIh|ryP MWfTRW5ITVJ?
SCC-9 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVTJR|UxRTF2LkGwNlEh|ryP NEfTbJZUSU6JRWK=
KINGS-1 NGH1N5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVTJR|UxRTF2LkG0NFIh|ryP MXfTRW5ITVJ?
SL-513 MkTJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnX0TWM2OD1zND6xPFch|ryP NHf5Z5JUSU6JRWK=
HLE M3uzXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF7FUIZKSzVyPUG0MlM5PTJizszN M2DoVnNCVkeHUh?=
SW1573 NYO0PIdUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUfJR|UxRTF2LkS0N|Uh|ryP MVHTRW5ITVJ?
KYSE-140 NUHLXllHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUfJR|UxRTF2Lk[zNlch|ryP MlqxV2FPT0WU
SK-PN-DW MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoT0TWM2OD1zND64NFAyKM7:TR?= NX6yZm1pW0GQR1XS
A253 NHjzTIFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXfHO48zUUN3ME2xOU4xPjJ3IN88US=> NVewR|RWW0GQR1XS
CAL-12T M3\IWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4TmZ2lEPTB;MUWuOFY3OiEQvF2= Ml3pV2FPT0WU
COLO-679 M{CydWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoG2TWM2OD1zNT63Olg{KM7:TR?= MUTTRW5ITVJ?
UACC-257 Mm\BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4XXOGlEPTB;MU[uNVIxOSEQvF2= NYTBZm5{W0GQR1XS
U-87-MG NVy0[o52T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWn6bpJEUUN3ME2xOk4{PTJ|IN88US=> NIiwOYJUSU6JRWK=
HCC1806 NHiwNoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHfvVpJKSzVyPUG2MlcxPzFizszN MWLTRW5ITVJ?
NCI-H2170 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnHJTWM2OD1zNz6yOFQ5KM7:TR?= NV;WcWNPW0GQR1XS
AGS MlrYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1viSGlEPTB;MUeuN|gxQCEQvF2= NUf0U4dmW0GQR1XS
MEL-HO MmqyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlfZTWM2OD1zNz63OVA{KM7:TR?= NH23dXVUSU6JRWK=
SW48 M2L3emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUL6RnFLUUN3ME2xO{44PzF4IN88US=> NFzO[29USU6JRWK=
HuP-T4 NUjBSGQ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXzpU2d3UUN3ME2xPE4xOjB4IN88US=> MUHTRW5ITVJ?
NCI-H720 NGrHZXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mnr2TWM2OD1zOD6xOFAzKM7:TR?= MlH1V2FPT0WU
RCC10RGB NXPFPZY{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVjJR|UxRTF6LkG2PVch|ryP NX2zW3dDW0GQR1XS
HD-MY-Z MlKxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4PkbGlEPTB;MUiuNlI2PCEQvF2= NIH5O4tUSU6JRWK=
A427 M1z3Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkXUTWM2OD1zOD61NFk1KM7:TR?= NUT3bVlKW0GQR1XS
HCC2998 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MW\JR|UxRTF6Lk[wOVEh|ryP NWXHZ3A{W0GQR1XS
EPLC-272H M4HQe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGPhWWFKSzVyPUG5MlA1OzRizszN NXzxcFJGW0GQR1XS
C32 NH\UUW5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVrJR|UxRTF7LkC0OUDPxE1? NXHYR3Q2W0GQR1XS
UMC-11 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoLPTWM2OD1zOT6yNVI{KM7:TR?= MWjTRW5ITVJ?
CaR-1 MkLDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFLGOlNKSzVyPUG5MlY5ODRizszN NFPCU2hUSU6JRWK=
KYSE-410 NFz2UolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXvJR|UxRTF7LkmxN|kh|ryP NHPtTYlUSU6JRWK=
HuCCT1 NUHpe4lOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGr3ZYlKSzVyPUKwMlYzQTRizszN NGDtcotUSU6JRWK=
LB996-RCC M{LM[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGf0c2JKSzVyPUKwMlcyPjhizszN MVHTRW5ITVJ?
KYSE-70 MornS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYDJR|UxRTJyLkiwOVkh|ryP MWrTRW5ITVJ?
CAL-72 NVP2TG9UT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYjJR|UxRTJyLkmxOUDPxE1? NYC4UHJ{W0GQR1XS
Capan-2 NHTJSlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3O1V2lEPTB;MkGuNFQyOyEQvF2= NV;Zend{W0GQR1XS
PANC-08-13 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnn6TWM2OD1{MT6yOVE2KM7:TR?= NUHMRXVEW0GQR1XS
SBC-1 Ml;iS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGC2OmdKSzVyPUKxMlMxQDFizszN M2rHeXNCVkeHUh?=
MFM-223 NUnhdIoxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{nRZWlEPTB;MkGuN|M1OiEQvF2= NEjEfW1USU6JRWK=
BB49-HNC MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3rYPGlEPTB;MkGuOVcyPiEQvF2= M2HoNHNCVkeHUh?=
SH-4 NVL5fYVxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUTJR|UxRTJzLk[2NVgh|ryP MkHjV2FPT0WU
HuO9 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVftcXVbUUN3ME2yNU46QDJ3IN88US=> M2HJOHNCVkeHUh?=
AM-38 NGrKeGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4fmdGlEPTB;MkKuNFQ5PSEQvF2= NGTJVXdUSU6JRWK=
A431 NF\uVo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml7kTWM2OD1{Mz6yNVE6KM7:TR?= MXfTRW5ITVJ?
YAPC MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHe1XZlKSzVyPUKzMlI3PTFizszN M{n5VnNCVkeHUh?=
LU-139 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnPKTWM2OD1{Mz60PFA6KM7:TR?= MXfTRW5ITVJ?
HEC-1 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml3MTWM2OD1{Mz60PVM4KM7:TR?= NVXzZZREW0GQR1XS
SCC-25 NXu4U|luT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGHlWppKSzVyPUK0MlMxODZizszN NH\6SJlUSU6JRWK=
HT-29 NVey[4ZKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1POZmlEPTB;MkSuN|gzOyEQvF2= M{T6TXNCVkeHUh?=
PC-14 NXLjXIw5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIrCW5RKSzVyPUK0MlY2PzFizszN MUPTRW5ITVJ?
Calu-6 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXGxW4RlUUN3ME2yOU42ODdzIN88US=> NUDlPHh1W0GQR1XS
SJRH30 NHSyXJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVXJR|UxRTJ3Lk[0PVYh|ryP MVPTRW5ITVJ?
ChaGo-K-1 NILlWpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIfQWZlKSzVyPUK2MlE3OjlizszN M1nvXnNCVkeHUh?=
IA-LM MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYLJR|UxRTJ4LkO2OFUh|ryP MknCV2FPT0WU
GP5d MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWHXXZdyUUN3ME2yOk41PDlzIN88US=> MlnzV2FPT0WU
NCI-H2291 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWLJR|UxRTJ4Lk[1OFEh|ryP Ml[1V2FPT0WU
BALL-1 NX\ScIZtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3jrdmlEPTB;Mk[uPVM6PyEQvF2= MnLRV2FPT0WU
HCC1954 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NI\hfHFKSzVyPUK2Mlk5ODhizszN Mkn0V2FPT0WU
NCI-H2452 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX;JR|UxRTJ5LkSxOlMh|ryP MU\TRW5ITVJ?
LU-99A MmjOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkDWTWM2OD1{Nz61OVgzKM7:TR?= NIfRUXNUSU6JRWK=
NTERA-S-cl-D1 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGq1WoRKSzVyPUK3MlczQTlizszN NH[4b49USU6JRWK=
PANC-10-05 M1vRbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYrCdodiUUN3ME2yO{44Pzd3IN88US=> NHLiVpBUSU6JRWK=
NCI-H2405 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{DLfGlEPTB;MkeuPVM5PyEQvF2= NWjJRox3W0GQR1XS
MDA-MB-415 NGThWFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVHJR|UxRTJ6LkSxN|ch|ryP NUGwb5NpW0GQR1XS
NCI-H2342 M3PJWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1\zdWlEPTB;MkiuOVI5OSEQvF2= NInNOZhUSU6JRWK=
TGBC24TKB NW\2cHdRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIn0S2RKSzVyPUK4MlcyOTdizszN MUHTRW5ITVJ?
LU-134-A MorkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnXwTWM2OD1{OD65NlYyKM7:TR?= MVfTRW5ITVJ?
SCC-4 NH;qSmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX:ybJhNUUN3ME2zNU4xPDl2IN88US=> M3fCTnNCVkeHUh?=
Saos-2 M2nsemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWXJR|UxRTNzLkmzNFYh|ryP NWqxe2ROW0GQR1XS
RERF-LC-MS M{THbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXXjeYpCUUN3ME2zNk45OjNzIN88US=> M3T5SnNCVkeHUh?=
M14 Ml;BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX7JR|UxRTN{Lkm3OlQh|ryP Mki1V2FPT0WU
HPAF-II NWG3eWp1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3;tbWlEPTB;M{OuOVAyOSEQvF2= MYTTRW5ITVJ?
NCI-H1755 NIXDXppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXLJR|UxRTN2LkOzNFUh|ryP MV3TRW5ITVJ?
D-392MG MkLCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4S4SmlEPTB;M{WuPFY4PCEQvF2= MY\TRW5ITVJ?
A704 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWrWT5RuUUN3ME2zOk4xPDJ5IN88US=> M4f1RnNCVkeHUh?=
CP50-MEL-B MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYO5b3pWUUN3ME2zOk4yQTFzIN88US=> MYHTRW5ITVJ?
EW-18 M1nnV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml60TWM2OD1|Nj60OVIh|ryP M3HUU3NCVkeHUh?=
WM-115 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWTDW5FDUUN3ME2zOk45ODl7IN88US=> NEjH[4RUSU6JRWK=
LU-65 MnHoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGrKdHVKSzVyPUO3MlE1OTdizszN MYrTRW5ITVJ?
NCI-H1563 NHvPTIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWr1dVMzUUN3ME2zO{4zPDh2IN88US=> NUHIdYh[W0GQR1XS
DBTRG-05MG NHXyXnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnHGTWM2OD1|OD6wOlkyKM7:TR?= M2\Bb3NCVkeHUh?=
NCI-H630 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXjJR|UxRTN6LkS3NVQh|ryP MWrTRW5ITVJ?
NCI-H1155 NGW0RpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWnJR|UxRTN7LkK0NkDPxE1? NXTwdJpGW0GQR1XS
OVACR-3 NUToW3A1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NY\5d5VDUUN3ME2zPU46OTl3IN88US=> MojTV2FPT0WU
OAW-42 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M33vOmlEPTB;NECuOFI2QCEQvF2= MnjMV2FPT0WU
JVM-2 NEnsTHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIHjR5pKSzVyPUSxMlI1OTVizszN Mnv1V2FPT0WU
C3A Mnv1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGDZR3dKSzVyPUSxMlM1PDdizszN M1rjcnNCVkeHUh?=
HT55 Mm\GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEnkfJFKSzVyPUSyMlI5PDFizszN NGTSXolUSU6JRWK=
OVCAR-4 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX3rW2oyUUN3ME20Nk4zQTd2IN88US=> Mni4V2FPT0WU
MEG-01 NF\hdohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnvNTWM2OD12Mj60OlE3KM7:TR?= NGrTUGVUSU6JRWK=
NCI-H82 NH\vWGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mly5TWM2OD12Mz65PFkzKM7:TR?= NXjUd|MzW0GQR1XS
JEG-3 MlqzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4LvW2lEPTB;NESuPVQ4KM7:TR?= MXHTRW5ITVJ?
BPH-1 MljrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M17XNWlEPTB;NE[uN|k6QCEQvF2= NXu2V4RxW0GQR1XS
MPP-89 M1PSWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1HZSmlEPTB;NEeuNlg6QCEQvF2= NXHiUIlqW0GQR1XS
ALL-PO NHjMWplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWDrU|BLUUN3ME20O{41OTh6IN88US=> MV7TRW5ITVJ?
HT NH:2bmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXnnXJA4UUN3ME20O{41QTJizszN NHPrfplUSU6JRWK=
NCI-H2347 NF65Z5pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NInTfXlKSzVyPUS4MlA4OTVizszN M4TJR3NCVkeHUh?=
A2780 NWDXNZNlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYDJR|UxRTR7LkSyNlgh|ryP NGjtPVRUSU6JRWK=
KARPAS-299 NHz4bYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUP2UYI2UUN3ME20PU42OTF7IN88US=> MoHRV2FPT0WU
NCI-H1651 Ml\SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGfsWVhKSzVyPUS5Mlg5OjFizszN NF[ydWJUSU6JRWK=

多くの細胞株試験データを見る場合、クリックしてください

体内試験 PD 0332991 indicates complete tumor stasis in a MDA-MB-435 xenograft at 150 mg/kg. PD 0332991 also shows broad-spectrum antitumor activity in multiple human tumor xenografts by eliminating phospho-Rb and the proliferative marker Ki-67 from tumor tissue and down-regulation of genes under the transcriptional control of E2F. [1]

お薦めの試験操作(参考用のみ)

キナーゼ試験:

[1]

+ 展開

Cdk Assays:

A stock solution of PD0332991 is prepared in DMSO. CDK assays are performed in 96-well filter plates. All CDK-cyclin kinase complexes are expressed in insect cells through baculovirus infection and purified. The substrate for the assays is a fragment (amino acids 792–928) of pRb fused to GST (GST·RB-Cterm). The total volume in each well is 0.1 mL containing a final concentration of 20 mM Tris-HCl, pH 7.4, 50 mM NaCl, 1 mM dithiothreitol, 10 mM MgCl2, 25 μM ATP (for CDK4-cyclin D1, CDK6-cyclin D2, and CDK6-cyclin D3) or 12 μM ATP (for CDK2-cyclin E, CDK2-cyclin A, and CDC2-cyclin B) containing 0.25 μCi of [γ-32P]ATP, 20 ng of enzyme, 1 μg of GST·RB-Cterm, and PD 0332991 (0.001-0.1μM). All components except the [γ-32P]ATP are added to the wells, and the plate is placed on a plate mixer for 2 min. The reaction is started by adding the [γ-32P]ATP and the plate is incubated at 25 °C for 15 min. The reaction is terminated by addition of 0.1 mL of 20% trichloroacetic acid and the plate is kept at 4  °C for at least 1 hour to allow the substrate to precipitate. The wells are then washed 5 times with 0.2 mL of 10% trichloroacetic acid and radioactive incorporation is determined with a β plate counter.
細胞試験:

[1]

+ 展開
  • 細胞株: Tumor cell lines including MDA-MB-435, ZR-75-1, T-47D, MCF-7, H1299, Colo-205, MDA-MB-468, H2009, CRRF-CEM and K562
  • 濃度: 0.01-1 μM
  • 反応時間: 24 hours
  • 実験の流れ:

    Cells are seeded at 2 × 104 per well in a 96-well plate and incubated overnight. PD 0332991 (0.01-1 μM) is added to the wells and incubated at 37 °C for another 24 hours. [14C]Thymidine (0.1 μCi) is added to each well and incorporation of the radiolabel is allowed to proceed for 72 hours. Incorporated radioactivity is determined with a β plate counter.


    (参考用のみ)
動物試験:

[1]

+ 展開
  • 動物モデル: Advanced stage human tumor xenografts including Colo-205, MDA-MB-435 breast, SF-295 glioblastoma, ZR-75-1 breast, PC-3 prostate, H125 lung, SW-620 colon, H23 lung and MDA-MB-468 breast (Rb negative) are established in severe combined immunodeficient mice.
  • 製剤: Dissolved in sodium lactate buffer (50 mM, pH 4.0)
  • 投薬量: 0-150 mg/kg
  • 投与方法: Given by gavage
    (参考用のみ)

溶解度 (25°C)

体外 Water 30 mg/mL (61.98 mM)
DMSO 3 mg/mL warmed (6.19 mM)
Ethanol Insoluble
体内 左から(NMPから)右の順に溶剤を製品に加えます:
Saline
混合させたのち直ちに使用することを推奨します。
6 mg/mL

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報

分子量 483.99
化学式

C24H29N7O2.HCl

CAS No. 827022-32-2
保管
in solvent
別名 N/A

便利ツール

モル濃度計算器

モル濃度計算器

解決のために必要とされるマス、ボリュームまたは濃度を計算してください。

マス (g) = 濃度 (mol/L) x ボリューム (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • マス
    濃度
    ボリューム
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備することを要求される希釈剤を計算してください. セレック希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 輸入 輸出 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

マス 濃度 ボリューム 分子量

臨床試験

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03007979 Not yet recruiting Breast Cancer|Breast Carcinoma|Cancer of Breast|Malignant Tumor of Breast Washington University School of Medicine February 28, 2017 Phase 2
NCT02907918 Not yet recruiting Breast Cancer|Cancer of Breast|Breast Carcinoma Washington University School of Medicine|Pfizer February 28, 2017 Phase 2
NCT01209598 Completed Sarcoma|Liposarcoma Memorial Sloan Kettering Cancer Center|Pfizer September 23, 2010 Phase 2
NCT03054363 Not yet recruiting Breast Cancer University of Colorado, Denver March 2017 Phase 1|Phase 2
NCT03024489 Not yet recruiting Head and Neck Cancer|Locally Advanced|Unresectable Mahidol University February 2017 Phase 1|Phase 2
NCT02947685 Not yet recruiting HER-2 Positive Breast Cancer|Estrogen Receptor Positive Breast Cancer Alliance Foundation Trials, LLC.|Pfizer|German Breast Group (GBG)|Fondazione Michelangelo|PrECOG, LLC.|The Australia and New Zealand Breast Cancer Trials Group (ANZBCTG)|Alliance Foundation Trials Biorepository - Washington State University|Alliance Foundation Trials Central Imaging Core Lab - Ohio State University|Mastering Breast Cancer Initiative, LLC|Mayo Clinic Statistics and Data Center|INC Research|SOLTI Breast Cancer Research Group February 2017 Phase 3

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

  • * 必須

CDKシグナル伝達経路

CDK Inhibitors with Unique Features

相関CDK製品

Tags: Palbociclib (PD-0332991) HClを買う | Palbociclib (PD-0332991) HCl ic50 | Palbociclib (PD-0332991) HCl供給者 | Palbociclib (PD-0332991) HClを購入する | Palbociclib (PD-0332991) HCl費用 | Palbociclib (PD-0332991) HCl生産者 | オーダーPalbociclib (PD-0332991) HCl | Palbociclib (PD-0332991) HCl化学構造 | Palbociclib (PD-0332991) HCl分子量 | Palbociclib (PD-0332991) HCl代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID